Drug intelligence / Profile preview

fluconazole + cefazolin

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous, Intramuscular

Overview

A combination of fluconazole, an azole antifungal agent, and a first-generation cephalosporin antibiotic. Fluconazole inhibits fungal cell membrane synthesis by targeting the cytochrome P450 enzyme 14α-demethylase, while cefazolin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. This combination provides coverage against both fungal and bacterial infections.

Other names: FLU + CZO

Targets

PBP (Penicillin-binding protein family)CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on fluconazole + cefazolin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluconazole + cefazolin.

Explore the full profile